Dana dhuwit saben siji saham adaptimmune.com (ADAP)

Simbol lan logo merek Adaptimmune Therapeutics (ADAP)

The approval of Tecelra has established Adaptimmune (ADAP) as a pioneer in cellular engineering. The development of the TCR ecosystem offers hope to patients with advanced tumors, while the implementation of laboratory robotics optimizes test validation. The cash per share in the daily price action on the GURU.Markets chart demonstrates liquidity, where the 0.00 level reflects the status of the company's financial stability parameter.

ADAP adaptimmune.com: Dhuwit awis saben siji saham ing interval 04.07.2022 - 15.11.2025

Rincian metrik komprehensif lan analitis adaptimmune.com (ADAP)

- rega pasar lan target rega analis:
- data dhuwit lan arus kas:
Ringkesan analisis perusahaan:ADAP (Adaptimmune Therapeutics plc)
Produk dadi Adaptimmune

This indicator determines the liquidity level available to each security holder. By analyzing the cash per share valuation, an investor tracks the issuer's capital dynamics. The metric is calculated by dividing the total cash and cash equivalents by the total number of shares. For Adaptimmune (ADAP), this figure confirms financial stability. The commercial success of T-cell therapy and partnership payments ensure a stable free cash flow.